̽���ϼ�

Under its terms, ̽���ϼ� will manufacture Harm Reduction Therapeutics’ naloxone nasal spray, RiVive™ (3.0 mg), for the emergency treatment of known or suspected opioid overdose.

Under the terms of the agreement, ̽���ϼ� is authorized to collaborate with its customers to evaluate BRL’s formulation technology to reduce viscosity and deliver high-concentration biologic products.

̽���ϼ� today announced their successful formulation design and clinical-phase manufacturing collaboration for an orally dosed small molecule in Grünenthal’s pipeline.

̽���ϼ� today announced the expansion of its UpTempo℠ platform process for the development and CGMP manufacturing of adeno-associated viral (AAV) vectors.

Krishnan will lead the company’s operational excellence strategy and spearhead a transformation based on Lean principles, designed to drive sustainable execution excellence enabling growth.

Vice President of Business Transformation Matt Blume, will host a panel session at the upcoming Bio Supply Management Alliance Conference, to be held at the Crowne Plaza Suites Hotel, Foster City, California, on March 8 – 9, 2023.

The report highlights ̽���ϼ�’s progress against its previously published targets and commitments in the areas of environmental, social, and governance (ESG).

̽���ϼ� today announced that its Global Director of Clinical Supply Management, Stephanie Graham, is to speak at the upcoming Clinical Outsourcing Group Conference, to be held in London, U.K., on Feb. 21-22, 2023.

The project has seen the site increase by approximately 30,000 square feet, which has allowed the installation of additional refrigerated and deep-frozen storage, and secondary packaging capabilities to be expanded.